摘要
目的:研究偏头痛患者应用降钙素基因相关肽(CGRP)拮抗剂联合普萘洛尔后临床疗效,及对患者脑血流速度的影响。方法:选取2020年1月-2022年4月我院收治的80例神经性偏头痛患者作为研究对象,根据抽签法均分为对照组和治疗组,每组40例。对照组给予盐酸普萘洛尔片口服治疗,治疗组给予CGRP拮抗剂与盐酸普萘洛尔片联合治疗,比较两组治疗前、治疗3个月后临床疗效、头痛改善情况、脑血管血流情况及不良反应发生情况。结果:治疗组总有效率高于对照组(P<0.05);治疗组头痛频次小于对照组,VAS评分低于对照组,头痛持续时间短于对照组(P<0.05);治疗组BA、VA、MCA流速低于对照组(P<0.05);治疗组不良反应总发生率低于对照组(P<0.05)。结论:CGRP拮抗剂联合盐酸普萘洛尔片对偏头痛患者的疗效优于单独应用盐酸普萘洛尔片,能减轻患者的头痛程度,减少头痛频次和头痛持续时间,降低脑血流速度及不良反应发生率,具有一定的临床应用价值。
Objective:To investigate the clinical efficacy of calcitonin gene-related peptide(CGRP)antagonist combined with propranolol in migraine patients and its influence on cerebral blood flow velocity.Methods:A total of 80 patients with neuropathic migraine admitted to our hospital from January 2020 to April 2022 were selected as the research objects,and were divided into the control group and the treatment group according to the lottery method,with 40 cases in each group.The control group was treated with oral propranolol hydrochloride tablets,while the treatment group was treated with CGRP antagonist combined with propranolol hydrochloride tablets.The clinical efficacy,headache improvement,cerebrovascular blood flow and adverse reactions were compared between the two groups before treatment and 3 months after treatment.Results:The total effective rate of the treatment group was higher than that of the control group(P<0.05).The headache frequency,VAS score and headache duration in the treatment group were lower than those in the control group(P<0.05).The flow rates of BA,VA and MCA in the treatment group were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the treatment group was lower than that in the control group(P<0.05).Conclusion:CGRP antagonist combined with propranolol hydrochloride tablets is better than propranolol hydrochloride tablets alone in the treatment of migraine patients.It can alleviate the degree of headache,reduce the frequency and duration of headache,reduce the cerebral blood flow velocity and the incidence of adverse reactions,which has certain clinical application value.
作者
于洋洋
白丽红
YU Yangyang;BAI Lihong(Department of Pharmacy,Jiamusi Hospital of Traditional Chinese Medicine,Jiamusi 154002,Heilongjiang,China)
出处
《中国药物滥用防治杂志》
CAS
2023年第7期1225-1228,1240,共5页
Chinese Journal of Drug Abuse Prevention and Treatment